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W. Rzeski4 and A. Wolski51Department of Biochemistry, M. Curie-Sklodowska University, Lublin, 2Division of General and Vascular
Surgery, Municipal Hospital, Rzeszow, Departments of 3General Microbiology, Institute of Microbiology,
M. Curie-Sklodowska University, Lublin, 4Virology and Immunology, Institute of Microbiology and
Biotechnology, M. Curie-Sklodowska University, and 5Division of Vascular Surgery, Public Clinical Hospital
no 4, Lublin, PolandObjectives. To create an antibiotic-modified vascular prosthesis with a prolonged bactericidal activity, susceptible to
endothelialisation.
Methods. We used a covalent method of gentamicin sulphate immobilisation to polyethylene terephthalate prosthesis sealed
with gelatin. Antibacterial activity was assayed in Luria-Bertani medium against Staphylococcus aureus, Escherichia
coli and Pseudomonas aeruginosa strains. Prosthesis endothelialisation was performed using bovine aorta endothelial
cells (BAEC).
Results. Gentamicin was bound to vascular prostheses in the amount of 12 g per kg of prosthesis. Ninety-seven percent of
antibiotic bound in covalent way and remained on the biomaterial for at least 30 days during shaking in PBS solution.
Gentamicin-modified prostheses exerted bactericidal or bacteriostatic effect on growth of clinical and reference bacterial
strains, prevented biofilm formation and were highly susceptible to endothelialisation. BAEC viability exceeded 90%, which
indicated that gentamicin-vascular prostheses were not toxic for these cells.
Conclusions. Covalent gentamicin immobilisation resulted in effective antibacterial protection of vascular prostheses
against clinical and reference strains of S. aureus, E. coli and P. aeruginosa and allowed for a strong adherence of
endothelial cells to antibiotic-modified prostheses.Keywords: Gelatin-sealed vascular prostheses; Covalent immobilisation; In vitro bacterial adherence; Endothelial cell
proliferation.The reported incidence of vascular graft infections
ranges between 0.5 and 5%.1 They are potentially
devastating complications of reconstructive arterial
surgery.2 Vascular prosthetic infections are associated
with a high rate of limb loss and mortality (up to 79
and 75% of cases, respectively)1,3 and may be caused
by perioperative contamination, postoperative wound
infection or systemic bacteraemia.4 Reduction of graft
infections may be obtained by impregnation of the
commercial prostheses with antibiotics (or any other
antiseptic chemicals) to prevent the bacterial adher-
ence.5 This effect was achieved by antibiotics adsorp-
tion to prostheses sealed with gelatin, collagen oring author. Prof. Grazyna Ginalska, Department of
, M. Curie-Sklodowska University, 3, Maria Curie-
q., 20-031 Lublin, Poland.
: ginal@hermes.umcs.lublin.pl
0419 + 06 $35.00/0 q 2005 Elsevier Ltd. All rights reseralbumin.6,7 An example of such procedures was
rifampicin ionic bonding to protein-sealed biomaterials;
however, it was shown that this antibiotic was quickly
eluted to perigraft tissues.2,7,8
The antibiotic-prostheses hybrids produced so far
lack the appropriate stability because their antibacterial
protection is limited to several days, depending on the
antibiotic and biomaterial type.5,9–11 To overcome this
problem, our group has been recently, working on
covalent gentamicin immobilisation to protein-coated
or silanized silica materials. We have shown in vitro the
stability of covalent bonds between the antibiotic and
keratin-coated silica matrices.12 Strong chemical stab-
ility was observed for gentamicin-modified gelatin-
sealed polyethylene terephthalate prostheses, with the
majority of antibiotic bound covalently.13 In this paper,
we present the long-lasting antibacterial properties of
gelatin-sealed polyethylene terephthalate vascularEur J Vasc Endovasc Surg 29, 419–424 (2005)
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and their high susceptibility to endothelialisation.Materials and MethodsMaterials
Gentamicin sulphate for immobilisation was obtained
from KRKA (Croatia) and used as solution at
concentration of 40 mg/ml in 0.1 M phosphate-buf-
fered saline (PBS), as described in The British
Pharmacopoeia.14 Gentamicin solution for standard
curve preparation was supplied by Fluka (Switzer-
land) at concentration of 1 mg/ml. Methanol and
2-propanol (HPLC grade) were obtained form Merck,
Germany. All other reagents and solvents for HPLC
were of analytical grade (Merck, Germany). Phthal-
dialdehyde reagent was freshly prepared by dissol-
ving 200 mg of o-phthaldialdehyde (OPA, Fluka,
Switzerland) in 1.5 ml methanol, adding 15 ml borate
buffer (2.5% boric acid adjusted to pH 10.4 by 40%
KOH), 0.5 ml mercaptoacetic acid and finally, by
adjusting pH to 10.4 with 40% potassium hydroxide.
Tricogelw vascular prostheses (Tricomed, Poland)
were made of polyethylene terephthalate fibres sealed
with pig gelatin.Gentamicin immobilisation
Covalent immobilisation of gentamicin on 1 cm2
pieces of Tricogelw prostheses was performed in
triplicate according to procedure described in our
patent pending No P-358934.15 Quantitative gentami-
cin estimation was performed according to the method
described in The British Pharmacopoeia16 using a
HPLC procedure (Gilson HPLC system, USA).
Chromatographic analysis was performed using
Nova-Pakw RP-18 (150!3.9 mm2; particle size: 5 um)
column (Waters, USA). Absorbance measurements
were made at wavelength 330 nm.In vitro drug release
Gentamicin-modified prosthesis samples (5!0.05 g)
were incubated in portions (20 ml) of 0.1 M PBS pH 7.4
in Erlenmayer flasks at 37 8C in a water bath shaker for
a 30-days period. Gentamicin concentration in
removed PBS was estimated every 7 days. The
experiment was performed in triplicate.Eur J Vasc Endovasc Surg Vol 29, April 2005Assay of antibacterial activity
Antibacterial activity of vascular prostheses modified
by covalent gentamicin immobilisation was tested
according to two procedures:by spot test: pieces of prostheses were put on agar
Luria-Bertani (LB) (Difco, USA) plates and covered
with semisolid (0.7%) LB medium containing
bacteria (1!106 cfu (colony forming units)/ml).
The plates were incubated at 37 8C for 18 h.
by incubation in liquid LB medium with gentle
shaking (35 rpm) at 37 8C with bacteria of concen-
trations indicated in Table 2.
Tests were performed against clinical bacterial
isolates from patients of Public Clinical Hospital no
4, Lublin, Poland (Escherichia coli from ear and urinal
tract, Staphylococcus aureus from throat and stools,
Pseudomonas aeruginosa from eyelids) and reference
strains (E. coli ATCC 25922, S. aureus ATCC 25923, P.
aeruginosa ATCC 27853). Prostheses with and without
gentamicin were sterilised by UV-light prior to
experiments (Philips lamp, 30 W/cm2, 0.5 h, from
distance of 15 cm). All experiments were performed
in triplicate. The average of three experiments (GSD)
is presented in overall count of bacteria by the serial
dilution method.Test of bacterial adhesion to gentamicin-modified vascular
prostheses
Bacterial adhesion to the prostheses was investigated
using the suspension of bacterial cells in LB broth (1!
106 cfu/ml). Pieces of gelatin-sealed vascular prosthe-
sis (control) or the gentamicin-modified prosthesis
were incubated with bacterial broth using gentle
agitation (35 rpm; 37 8C, 48 h). Prosthesis pieces were
subsequently taken out from the broth and washed out
three times with 50 ml of sterile distilled water to
remove all non-adhered bacteria.
Prosthesis samples for scanning electron microsco-
phy were prepared according to method of Mercier et
al.17 Prostheses were fixed in 3% (v/v) glutaraldehyde
(Sigma, USA) in 0.1 M PBS with 8% sucrose for 2 h at
4 8C and kept overnight in 0.1 M PBS at 4 8C. The
prostheses were subsequently washed three times for
10 min in 0.2 M cacodyl buffer (Sigma, USA) pH 7.4.
Then the samples were fixed in 1% (w/v) OsO4 for 1 h
at 4 8C and dehydrated (each step for 15 min at R/T) in
series of alcohol–water mixtures (70, 95, 100% ethanol)
and then in series of ethanol–acetone mixtures (30, 50,
70, 100% acetone). Dehydrated samples were dried in
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dryer (Bal-Tec, Switzerland), coated with gold–palla-
dium by a high resolution sputtering system Polaron
SC 7640 (Polaron, UK) and examined using a scanning
electron microscope Tesla BS300 (Tesla, Czech Repub-
lic) operated at 15 kV. A Satellite TC computer
program (Tescan, UK) was used to perform image
analysis.Bovine aorta endothelial cell culture
Bovine aorta endothelial cell culture (BAEC) was
prepared as previously described.18 Vessels isolated
from freshly slaughtered steers and heifers were
clumped before dissection from surrounding tissue,
excised, rinsed with PBS and filled with 0.25% trypsin
solution. After 30 min incubation at 37 8C, the endo-
thelial cell suspension was collected and centrifuged at
250g for 10 min. The cell pellet was resuspended in
culture medium and transferred into the 75 ml tissue
culture flasks (Nunc, Denmark). Culture medium
consisted of Dulbecco’s modified Eagle medium
(DMEM) (Sigma, USA), 10% fetal bovine serum
(FBS) (Life Technologies, Germany), penicillin
(100 U/ml) and streptomycin (100 U/ml) (Sigma,
USA). The cells were grown at 37 8C in a humidified
atmosphere of 5% CO2 in air. Endothelial cell
morphology was confirmed by typical cobblestone
appearance as well as by staining for von Willebrand
factor (Dakopatts, Denmark). For experiments, BAEC
at passage 5–8 were used.Table 1. Gentamicin immobilisation on gelatine-sealed vascular
prostheses
Gentamicin forms Concentration of gentamicin (mg/ml)
Before
immobilisation
After
immobilisationCell test design
Pieces of vascular prostheses were placed in a 24-well
microplate (Nunc, Denmark) and incubated in culture
medium at 37 8C overnight. The prosthesis samples
were inoculated with 2.5!104 BAEC suspended in a
fresh culture medium. Starting at 48 h, culture
medium was changed every day. Cell growth was
assessed after 48, 72, 96 and 144 h. Cells were detached
from prosthesis surface by 0.25% trypsin-EDTA
solution (Sigma, USA) and counted in a Thoma
hemocytometer. Cell viability was determined by
0.4% Trypan Blue exclusion. For visualisation, pros-
thesis fragments were washed in PBS, fixed in cold
methanol for 5 min and stained with Giemsa for 30 min.C1 2.973 1.811
C1a 1.146 0.666
C2a 0.490 0.300
C2 0.632 0.359
Total amount of
gentamicin
5.242 3.138Confocal microscopy
Prosthesis pieces covered with BAEC (obtained in the
previous experiment) were washed twice in PBSand subsequently stained with 3,3 0 dihexyloxacarbo-
cyanine iodine (DIO3(6)) (5 uM/ml) for 10 min in the
dark. Specimens were examined under the confocal
microscope (LSM-5, Pascal, Zeiss, Germany) at 514 nm.ResultsGentamicin immobilisation
We demonstrated that each of four predominate
structural forms (C1, C1a, C2, C2a) of gentamicin
bound to gelatin-coated prosthesis in different
amounts (Table 1). Using 5.2 mg/ml of gentamicin
solution we found the prosthesis to contain 12,620 mg
of the antibiotic per kg, with immobilisation yield of
40.15%.In vitro drug release
About 3% of the gentamicin initially bound to
Tricogelw prostheses was released from the biomater-
ial during the 1st 7 days of shaking in buffered saline
(PBS) at 37 8C (which was equal to 380 mg of antibiotic
released from 1 kg of prosthesis). Ninety-seven per-
cent of the antibiotic remained on the matrix for at
least 30 days (Fig. 1).Assay of antibacterial activity
Estimation of antibacterial properties of gentamicin-
modified prostheses was performed using two pro-
cedures. In the spot test, the zones of growth inhibition
around these prosthesis samples were measured for
reference bacterial strains: 37G1 mm for E. coli, 35G
1 mm for S. aureus and P. aeruginosa. The zones
observed for clinical isolates of these bacteria ranged
between 8 and 10 mm. In a second procedure, the
growth of the bacterial cells in liquid LB medium with
the antibiotic-modified prostheses was tested for
28 days. The results (Table 2) show that theEur J Vasc Endovasc Surg Vol 29, April 2005
Fig. 1. Release of gentamicin from vascular prosthesis during
30 days of incubation in PBS with shaking at 37 8C.
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effects on all bacteria used in these experiments. This
effect was bactericidal for each tested bacterial strain
(complete inhibition of bacterial growth). Only in the
case of a very high initial concentration of reference
bacterial strain did the effect of immobilised drug
become bacteriostatic (Table 2).Test of bacterial adhesion to gentamicin-modified vascular
prostheses
SEM photographs and microbiological tests on agar
plates revealed that the surfaces of gentamicin–
Tricogelw prostheses after incubation with three
bacterial strains were free both of bacterial cells and
biofilm, contrary to control prostheses without anti-
biotic. Fig. 2 presents this effect for S. aureus—a
representative bacterial species responsible for biofilm
formation.19 During microscopic observations of gen-
tamicin-modified prostheses, only single bacterial cells
were found on their surfaces. However, these bacteria
were unviable as was confirmed by microbiological
tests with these prosthesis samples incubated in liquidTable 2. Inhibitory effect of immobilised gentamicin bacterial growt
Strain MIC of gentamicin (mg/ml) Initial n
Escherichia coli
(a) Isolated from ear 1.0 4.0!10
(b) Isolated from urinary tract 1.5 4.0!10
(c) ATCC 25922 4.0 4.0!10
(d) ATCC 25922 5.0 4.0!10
Staphylococcus aureus
(a) Isolated from throat 1.0 1.9!10
(b) Isolated from stools 1.0 1.9!10
(c) ATCC 25923 3.0 1.9!10
(d) ATCC 25923 4.5 1.9!10
Pseudomonas aeruginosa
(a) Isolated from eyelids 3.0 5.9!10
(b) ATCC 27853 0.5 5.9!10
(c) ATCC 27853 0.8 5.9!10
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gentamicin-modified prostheses were incubated with
E. coli and P. aeruginosa (data not shown).Prostheses endothelialisation
Growth of BAEC on gentamicin-modified and control
(without the antibiotic) biomaterial samples was
tested in vitro. The results indicated that BAEC
attachment and growth on both gentamicin-modified
and control prostheses were similar (Fig. 3). The cell
numbers increased within culture time for both
prostheses (with and without antibiotic) reaching the
highest values at 144th h of culture. The experiment
was terminated at 144 h as the May–Gru¨nwald–
Giemsa of prosthesis samples with and without
gentamicin showed confluent monolayer on the
prosthetic surfaces (data not shown). During the
experiment, the cell viability exceeded 90% (Table 3).
The observation using confocal microscope showed
typical cobblestone morphology of growing endo-
thelial cells on surfaces of both prostheses (Fig. 3).Discussion
The problem of vascular grafts infection may cause
devastating complications in reconstructive arterial
surgery. Therefore, vascular surgeons are interested in
new solutions in this field. Covalent immobilization of
antibiotics on vascular prostheses seems to be the most
effective solution providing stable complexes of
durable antibacterial activity. According to Earnshaw,5
it is not clear whether the antibiotic should be bound
tightly to the graft in high concentration or it should be
released in controlled way into perigraft tissues. The
optimal antibiotic (of a broad or narrow spectrum) and
duration of its attachment to the prostheses are noth in LB medium with shaking at 37 8C for 28 days
umber of bacteria (cfu/ml) Number of bacteria (cfu/ml)!107GSD
6 0
6 0
6 0
8 8.0G2.0
7 0
7 0
7 0
9 9.5G1.5
6 0
6 0
8 2.9G0.5
Fig. 2. Test of adhesion of Staphylococcus aureus to vascular prostheses modified by gentamicin (A, control prostheses; B,
prostheses with antibiotic; bf, biofilm; bcl, living bacterial cells; bcu, unviable bacterial cells).
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present on the prostheses for at least several days and
reveal an activity against the graft infecting pathogens.
Up to now, the majority of research on this topic
describes rifampicin bound to gelatin-, collagen- or
albumin-sealed vascular prostheses in passive or ionic
mode.1,2,4,7,8,11 However, prostheses soaking in anti-
biotic solution (passive adsorption) is an ineffective
process as the drug is eluted from the grafts within at
last 4–7 days after the implantation by circulating
blood and other fluids.20,21 Ionic rifampicin bonding to
biomaterial is also ineffective and allows for the
antibacterial protection of prostheses only up to 10
days.20,21 Then, the amount of antibiotic remaining on
prosthesis drops below minimal inhibition concen-
tration (MIC).2,9,11,20,22 Despite this, Strachan and
coworkers9 argued for the use of antibiotic-impreg-
nated grafts for patients of increased infection risk. In
vivo experimental studies showed that reinfection
rates were slightly reduced when the rifampicin-
impregnated grafts were used, though MRSA infec-
tions caused more serious difficulties.21,23
Our results obtained for covalently-modified pros-
theses show that during the 1st days after immobiliz-
ation only 3% of antibiotic was released from the
biomaterial. This small quantity of drug may allowTable 3. Evaluation of endothelial cells growth on vascular
prostheses without and with immobilised gentamicin
Time (h) Cell number!104GSEM
Control prostheses Prostheses with gentamicin
48 5.0G2.0 5.0G2.0
72 13.5G0.5 12.0G7.0
96 26.5G4.5 26.5G2.5
120 32.75G1.75 36.25G2.75
144 59.0G0.0 58.0G0.0
SEM, standard error of mean.protection of the perigraft tissues just after the
prosthesis implantation. Simultaneously, the amount
of antibiotic remaining on the prosthesis is sufficient to
protect the graft for a long time because the gelatin is
gradually digested and detached from the graft
together with the antibiotic. According to our results,
this modification may protect the prosthesis surface
against bacterial cell attachment and biofilm formation.
It should be stressed that this procedure of gentamicin
immobilisation did not influence the properties of the
vascular prosthesis and allowed for BAEC growth.
These highly promising results require further studies
using human endothelial cells and fibroblasts.
It seems that covalent antibiotic-modification of
knitted prostheses made of polyethylene terephthalate
is of practical significance because it may minimise
bacterial growth and adherence to the implantable
biomaterial, particularly in cases of high risk patients
(with diabetes, distal skin necrosis or previously
subjected to surgery.5) This is of special importance
because infections of these prostheses are more
frequent than these of prostheses made of polytetra-
fluoroethylene (PTFE).24 These results require confir-
mation by further in vivo experiments concerning
clinical research on animals and in case of positive
results—also on people. However, we may assume
that covalent antibiotic modification of protein-sealed
vascular prostheses is a highly promising technique in
graft infections prophylaxis.Acknowledgements
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Fig. 3. Graphs of endothelial cells using a confocal micro-
scophy technique (A, control prosthesisCBAEC; B, genta-
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